ATTRACT | ATTRACT-1 Study | Researching ASA404 In Cancer Treatment
ATTRACT Clinical Trial Website - ATTRACT Logo
Search This Website:
Novartis Oncology Logo
U.S. Flag - Click If U.S. Resident for U.S. ATTRACT Clinical Trial Website Click here to email this page Click here to print this page
Antivascular Targeted Therapy Researching ASA404 in Cancer Treatment ATTRACT Clinical Trial Website Header – Blue Graphic ATTRACT Clinical Trial Website Header – Image of Couple
Home ATTRACT - 1

ATTRACT–1

ATTRACT-1 (Antivascular Targeted Therapy: Researching ASA404 in Cancer Treatment) is a Phase III clinical trial which is conducted at more than 200 sites in 20 countries. ATTRACT-1 is a randomized, double-blind, placebo-controlled, multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC) of squamous or nonsquamous histology. The clinical trial consists of 1,200 lung cancer patients who are assigned to one of the following cancer treatment arms in a ratio of 1:1: ASA404 1800 mg/m2 plus chemotherapy (carboplatin/paclitaxel) or placebo plus chemotherapy (carboplatin/paclitaxel) as a control. Cancer treatment is being given for up to six cycles, with one cycle equaling 21 days and total treatment equaling 126 days (4.2 months).